Compare T-Rex 2X Long MSTR Daily Target ETF (MSTU) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Rex 2X Long MSTR Daily Target ETF vs Neurocrine Biosciences Inc — how do they compare? T-Rex 2X Long MSTR Daily Target ETF trades at $39.86 (market cap $809.00M), while Neurocrine Biosciences Inc trades at $142.36 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 17.8× T-Rex 2X Long MSTR Daily Target ETF's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, T-Rex 2X Long MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold T-Rex 2X Long MSTR Daily Target ETF for 18 Days and Neurocrine Biosciences Inc for 23 Days on average.
| MSTU | NBIX | |
|---|---|---|
Market Cap | $809.00M | $14.36B |
Volume | 4,577,465 | 1,237,180 |
Sector | Leveraged / Inverse | Health |
52-Week High | $451.00 | $185.50 |
52-Week Low | $14.60 | $123.10 |
Typical Hold Time | 18 Days | 23 Days |
Enterprise Value | — | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTU trades at $40.50, up 2.66% with a bearish technical signal from moving averages while oscillators remain neutral. The stock faces significant resistance at $41-$43 levels with support at $37-$35. Recent corporate actions include a 10:1 reverse stock split effective August 24, 2026, and a $0.29 dividend declaration for H2-2026.
The leveraged ETF structure presents both opportunity and risk - offering amplified exposure to MSTR but with daily rebalancing that can erode value during volatility. Key risks include the compounding effect of daily leverage and Bitcoin price sensitivity. Investors should monitor the underlying stock's fundamentals and Bitcoin market dynamics closely.
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About T-Rex 2X Long MSTR Daily Target ETF
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
